HERE WE are peeking out from the bunker and all we see is biowreckage. The AMEX Biotechnology Index is down about 30% since the beginning of the year and last year’s high-flying genomic stocks are lying there smoldering with the likes of Amgen and Immunex. What’s a CEO to do?

Well, for one, don’t despair. In this case, what looks broken does not need repair. The entire market has gotten crushed and young genomics companies could do very little to avoid getting taken down with the rest of the market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.